Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14

1.

Evaluation of anti-insulin receptor antibodies as potential novel therapies for human insulin receptoropathy using cell culture models.

Brierley GV, Siddle K, Semple RK.

Diabetologia. 2018 Jul;61(7):1662-1675. doi: 10.1007/s00125-018-4606-2. Epub 2018 Apr 27.

2.

Severe insulin resistance in disguise: A familial case of reactive hypoglycemia associated with a novel heterozygous INSR mutation.

Innaurato S, Brierley GV, Grasso V, Massimi A, Gaudino R, Sileno S, Bernardini S, Semple R, Barbetti F.

Pediatr Diabetes. 2018 Jun;19(4):670-674. doi: 10.1111/pedi.12632. Epub 2018 Feb 7.

PMID:
29411486
3.

Acute knockdown of the insulin receptor or its substrates Irs1 and 2 in 3T3-L1 adipocytes suppresses adiponectin production.

Groeneveld MP, Brierley GV, Rocha NM, Siddle K, Semple RK.

Sci Rep. 2016 Feb 18;6:21105. doi: 10.1038/srep21105.

4.

Blood-based protein biomarker panel for the detection of colorectal cancer.

Fung KY, Tabor B, Buckley MJ, Priebe IK, Purins L, Pompeia C, Brierley GV, Lockett T, Gibbs P, Tie J, McMurrick P, Moore J, Ruszkiewicz A, Nice E, Adams TE, Burgess A, Cosgrove LJ.

PLoS One. 2015 Mar 20;10(3):e0120425. doi: 10.1371/journal.pone.0120425. eCollection 2015.

5.

Delineation of the IGF-II C domain elements involved in binding and activation of the IR-A, IR-B and IGF-IR.

Henderson ST, Brierley GV, Surinya KH, Priebe IK, Catcheside DE, Wallace JC, Forbes BE, Cosgrove LJ.

Growth Horm IGF Res. 2015 Feb;25(1):20-7. doi: 10.1016/j.ghir.2014.09.004. Epub 2014 Oct 30.

PMID:
25458127
6.

Claudin-1 Expression Is Elevated in Colorectal Cancer Precursor Lesions Harboring the BRAF V600E Mutation.

Caruso M, Fung KY, Moore J, Brierley GV, Cosgrove LJ, Thomas M, Cheetham G, Brook E, Fraser LM, Tin T, Tran H, Ruszkiewicz A.

Transl Oncol. 2014 Aug;7(4):456-63. doi: 10.1016/j.tranon.2014.05.009. Epub 2014 Jun 19.

7.

Performance of serum lipocalin 2 as a diagnostic marker for colorectal cancer.

Fung KY, Priebe I, Purins L, Tabor B, Brierley GV, Lockett T, Nice E, Gibbs P, Tie J, McMurrick P, Moore J, Ruszkiewicz A, Burgess A, Cosgrove LJ.

Cancer Biomark. 2013;13(2):75-9. doi: 10.3233/CBM-130335.

PMID:
23838135
8.

Serum concentrations of brain-derived neurotrophic factor (BDNF) are decreased in colorectal cancer patients.

Brierley GV, Priebe IK, Purins L, Fung KY, Tabor B, Lockett T, Nice E, Gibbs P, Tie J, McMurrick P, Moore J, Ruszkiewicz A, Burgess A, Cosgrove LJ.

Cancer Biomark. 2013;13(2):67-73. doi: 10.3233/CBM-130345.

PMID:
23838134
9.

A combined free-flow electrophoresis and DIGE approach to identify proteins regulated by butyrate in HT29 cells.

Fung KY, Cursaro C, Lewanowitsch T, Brierley GV, McColl SR, Lockett T, Head R, Hoffmann P, Cosgrove L.

Proteomics. 2011 Mar;11(5):964-71. doi: 10.1002/pmic.201000429. Epub 2011 Jan 31.

PMID:
21280223
10.

Butyrate-induced apoptosis in HCT116 colorectal cancer cells includes induction of a cell stress response.

Fung KY, Brierley GV, Henderson S, Hoffmann P, McColl SR, Lockett T, Head R, Cosgrove L.

J Proteome Res. 2011 Apr 1;10(4):1860-9. doi: 10.1021/pr1011125. Epub 2011 Mar 3.

PMID:
21235278
11.

A human monoclonal antibody against insulin-like growth factor-II blocks the growth of human hepatocellular carcinoma cell lines in vitro and in vivo.

Dransfield DT, Cohen EH, Chang Q, Sparrow LG, Bentley JD, Dolezal O, Xiao X, Peat TS, Newman J, Pilling PA, Phan T, Priebe I, Brierley GV, Kastrapeli N, Kopacz K, Martik D, Wassaf D, Rank D, Conley G, Huang Y, Adams TE, Cosgrove L.

Mol Cancer Ther. 2010 Jun;9(6):1809-19. doi: 10.1158/1535-7163.MCT-09-1134. Epub 2010 Jun 1.

12.

Silencing of the insulin receptor isoform A favors formation of type 1 insulin-like growth factor receptor (IGF-IR) homodimers and enhances ligand-induced IGF-IR activation and viability of human colon carcinoma cells.

Brierley GV, Macaulay SL, Forbes BE, Wallace JC, Cosgrove LJ, Macaulay VM.

Endocrinology. 2010 Apr;151(4):1418-27. doi: 10.1210/en.2009-1006. Epub 2010 Feb 23.

PMID:
20179263
13.

Differential activation of insulin receptor substrates 1 and 2 by insulin-like growth factor-activated insulin receptors.

Denley A, Carroll JM, Brierley GV, Cosgrove L, Wallace J, Forbes B, Roberts CT Jr.

Mol Cell Biol. 2007 May;27(10):3569-77. Epub 2007 Feb 26. Erratum in: Mol Cell Biol. 2007 Sep;27(17):6264.

14.

Differential activation of insulin receptor isoforms by insulin-like growth factors is determined by the C domain.

Denley A, Brierley GV, Carroll JM, Lindenberg A, Booker GW, Cosgrove LJ, Wallace JC, Forbes BE, Roberts CT Jr.

Endocrinology. 2006 Feb;147(2):1029-36. Epub 2005 Oct 20.

PMID:
16239300

Supplemental Content

Loading ...
Support Center